Home / Company
Company overview
A biopharmaceutical company developing treatments to combat disorders caused by disruption of neuronal signaling.
The mission
Conditions with few or poor options
The mission of the Company is to develop innovative and revolutionary treatments to combat disorders caused by disruption of neuronal signaling.
We are developing treatment options that address conditions affecting millions of people, but for which there are limited or poor treatment options, including obstructive sleep apnea, attention deficit hyperactivity disorder, epilepsy, chronic pain and spinal cord injury.
The pipeline is built on broad patent portfolios across two distinct drug platforms, ResolutionRx and EndeavourRx.
Organization
The people named publicly
The company publishes an organization chart and names its scientific leadership and its officers. Only the roles the company states are repeated here.
Arnold S. Lippa, PhD
Chief Scientific Officer
Described the first non-benzodiazepine to show GABAA receptor heterogeneity, and led the ocinaplon Phase 2 work — the scientific basis of the GABAkine programme.
Jeffrey M. Margolis
SVP, CFO, Secretary, Treasurer · Board member
The investor and media contact the company publishes, and the uploader of its investor briefings.
Governance
Board and policies
The company publishes its board of directors, a conflicts-of-interest policy and social-media guidelines. In January 2024 it announced the appointment of Dr. Dariusz Naziek to the Board of Directors.
RespireRx is incorporated in Delaware and headquartered at 126 Valley Road, Suite C, Glen Rock, New Jersey.